- Buyers' Guide
- VIV Asia 2017
- Contact Us
China’s animal vaccine industry has been growing fast. The market maintained an average annual growth rate of 13.6 per cent in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0 per cent YoY, according to a new report published by Research and Markets.
Merck’s animal health division, formerly known as Intervet/Schering-Plough Animal Health, has now been christened Merck Animal Health. It will be known as MSD Animal Health outside the United States and Canada.
“The name change reflects Merck’s commitment to animal health and its complementary role to the overall business,” said Raul Kohan, President of Merck Animal Health. “We are unwavering in our commitment to veterinarians, producers, pet owners and society as a whole. We aim to generate additional value and sustained growth by continuing to provide integrated solutions with innovative animal health products and services to meet the evolving needs of our customers.”
Mr. Kohan continued, “With the scientific and business backing of Merck, Merck Animal Health possesses the necessary mix of resources to enhance our position as an industry leader."
Merck Animal Health is a global leader in the research, development, manufacturing and sale of veterinary medicines and vaccines, with a strong presence in biologics and pharmaceuticals. The division generated global sales of US$2.9 billion in 2010.
Intervet/Schering-Plough Animal Health recently announced that it has opened a specialized filling and freeze-drying unit for veterinary vaccines at its Biosciences Center Boxmeer in the Netherlands.
Climate change and increased urbanisation are posing new challenges to animal disease prevention and control.
GLOBAL ANIMAL HEALTH company Merial and the Australian company Imugene have signed a comprehensive agreement allowing Merial to obtain exclusive rights to Imugene vector technology.